Pre-diabetes
Conditions
Keywords
Resveratrol, Diabetes Mellitus, Diabetes Mellitus, Type 2, Insulin Resistance, Glucose Metabolism Disorders, Metabolic Diseases, Endocrine System Diseases, Hyperinsulinism, Anti-Inflammatory Agents, Non-Steroidal, Analgesics, Non-Narcotic, Analgesics, Sensory System Agents, Peripheral Nervous System Agents, Physiological Effects of Drugs, Pharmacologic Actions, Anti-Inflammatory Agents, Therapeutic Uses, Antirheumatic Agents, Antineoplastic Agents, Phytogenic, Antineoplastic Agents, Antioxidants, Molecular Mechanisms of Pharmacological Action, Protective Agents, Enzyme Inhibitors, Platelet Aggregation Inhibitors, Hematologic Agents, Antimutagenic Agents, Anticarcinogenic Agents, Central Nervous System Agents, Brown Adipose Tissue
Brief summary
The main objective of the study is to investigate if resveratrol supplementation can improve overall and muscle-specific insulin sensitivity in first-degree relatives of type 2 diabetic patients. As a secondary objective the investigators want to investigate whether the improved insulin sensitivity can be attributed to improved muscle mitochondrial oxidative capacity and a reduced intrahepatic and cardiac lipid content. Furthermore, in a subset of the participants the investigators want to investigate the effect of resveratrol on glucose uptake in brown adipose tissue.
Interventions
DIETARY_SUPPLEMENTplacebo
A placebo will given for 30 days or 34 days (if included in brown adipose tissue measurement), twice daily. One pill will be provided with lunch, and the other pill will be provided with dinner.
DIETARY_SUPPLEMENTresveratrol
resveratrol will be given for 30 days or 34 days (if included in brown adipose tissue measurement), twice daily. One pill, which contains 75 mg of resveratrol, will be provided with lunch, and the other pill, also containing 75 mg will be given with dinner. So in total a dose of 150 mg/day will be given.
Sponsors
DSM Nutritional Products, Inc.
Diabetes Fonds
Maastricht University Medical Center
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
MALE
Age
40 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Male sex * Age: 40-70 years * BMI 27-35 kg/m2 * Has first-degree relative(s) diagnosed with type 2 diabetes * Sedentary * Not more than 2 hours of sports a week * No active job that requires strenuous physical activity * Stable dietary habits: no weight gain or loss \> 5kg in the last three months * Insulin resistant: glucose clearance rate below \< 350 ml/kg/min, as determined using OGIS120 * Willingness to abstain from resveratrol-containing food products * Subjects will only be included when the dependent medical doctor of this study approves participation after evaluating data obtained during screening
Exclusion criteria
* Use of anticoagulants * Uncontrolled hypertension * Haemoglobin \<7.8 mmol/l * In case of an abnormal ECG in rest: this will be discussed with the responsible medical doctor * HBA1C \> 6.5% * Diagnosed with type 2 diabetes * Medication use known to interfere with glucose homeostasis/metabolism * Current alcohol consumption \> 20 grams/day * Subjects who don't want to be informed about unexpected medical findings during the screening /study, or do not wish that their physician is informed, cannot participate in the study. * Subjects who intend to donate blood during the intervention or subjects who have donated blood less than three months before the start of the intervention. * Participation in another biomedical study within 1 month before the first screening visit * Any condition, disease or abnormal laboratory test result that, in the opinion of the Investigator, would interfere with the study outcome, affect trial participation or put the subject at undue risk * Any contra-indication to MRI scanning. These contra-indications include patients with following devices: * Central nervous system aneurysm clip * Implanted neural stimulator * Implanted cardiac pacemaker of defibrillator * Cochlear implant * Insulin pump * Metal containing corpora aliena in the eye or brains
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| insulin sensitivity: overall, muscle- and liver specific | 30 days after supplementation | Hyperinsulinemic euglycemic clamp combined with indirect calorimetry: Glucose infusion rate (GIR), rate of appearance and disappearance of glucose (Ra, Rd), endogenous glucose production (EGP), oxidative and non-oxidative glucose disposal, carbohydrate and lipid oxidation, energy expenditure. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| muscle mitochondrial oxidative capacity (in vivo and ex vivo) | 30 days after supplementation | In vivo: Phosphocreatine levels will be measured by P-MRS (before, during, and after exercise) as a marker for in vivo mitochondrial function in the vastus lateralis muscle. Ex vivo mitochondrial function in skeletal muscle will be measured by oxygen consumption in muscle fibres (muscle biopsy) on lipid-derived and carbohydrate-derived substrates. |
| intramyocellular lipid content | 30 days after supplementation | Skeletal muscle lipid accumulation measured by immunohistochemistry in muscle biopsy from vastus lateralis muscle |
| intrahepatic lipid content | 30 days after supplementation | Intrahepatic lipid content measured with H-MRS |
| heart function | 30 days after supplementation | Cardiac function: diastolic and systolic heart function will be measured with ultrasound |
| brown adipose tissue activity | 34 days after supplementation | subjects will be exposed to an individualized cooling protocol, after which an 18F-FDG PET/CT scan is made |
| intracardiac lipid content | 30 days after supplementation | Intracardiac lipid content measured with H-MRS |
Other
| Measure | Time frame |
|---|---|
| Maximal aerobic capacity (VO2max) | 27 days after supplementation |
| Blood pressure | 30 days after supplementation |
Countries
Netherlands
Outcome results
None listed